Find out which weight loss injections work best, how fast you can expect results, and whether combining them with other ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.

Drugs such as Wegovy, Ozempic, and Saxenda have quickly become household names. But are these weight loss medications right ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

As mentioned above, there’s currently a shortage of GLP-1 injections. Compounding pharmacies can create compounded versions to meet the demand. If a healthcare provider recommends you try ...